Treatment of Symptomatic Ventricular Premature Complexes

Initial Assessment and Risk Stratification

The American College of Cardiology notes that VPCs are common and increase in frequency with age, with longer-term monitoring showing PVCs in about 50% of all people with or without heart disease 2, 3
Risk factors for PVC-induced cardiomyopathy include high PVC burden (>10-15% of total heartbeats, with highest risk at >20-24%) 1
The American Heart Association suggests that a short coupling interval of PVCs (<300 ms) is a risk factor for PVC-induced cardiomyopathy 1
Wider QRS complexes (>160 ms) are also a risk factor for PVC-induced cardiomyopathy 1
Very frequent PVCs (>10,000 to 20,000 per day) can be associated with depressed left ventricular function 3

The American College of Cardiology recommends that no specific therapy is recommended for asymptomatic or mildly symptomatic patients with PVCs without other risk factors for sustained arrhythmias (Class III recommendation) 4, 5
Lifestyle modifications such as reducing caffeine, alcohol, and sympathomimetic agents can be beneficial 1
Beta-blockers are recommended as initial treatment for symptomatic PVCs 1
Catheter ablation is indicated for patients with highly symptomatic, uniform morphology PVCs who are potential candidates (Class I recommendation) 4, 5

The American College of Cardiology notes that in post-MI patients, suppression of ventricular ectopy using flecainide, encainide, or moricizine was associated with increased mortality (CAST trial) 4, 2
Class I sodium channel-blocking medications (e.g., quinidine, flecainide) increase risk of death in patients with reduced LVEF 2
Optimize heart failure medications according to current guidelines 1
Consider amiodarone as a second-line agent in patients with structural heart disease 1

Treatment with catheter ablation can restore normal LV function in up to 82% of patients within 6 months 1
Monitor PVC burden reduction after initiating therapy and follow LV function to document improvement 1

Antiarrhythmic drugs can have proarrhythmic effects, especially in patients with structural heart disease 4, 2